RxDoctor Payments DataLook up a doctor →

Daniel Anderson, MD

Hematology & Oncology · Saint Paul, MNNPI 1710949920

Payments from drug & device makers

$7,323,640in general payments, 2019–2025

Across 529 payments — averaging $13,844 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.4M
  • Merck$2.4M
  • Amgen$532K
  • Pfizer$488K
  • Takeda Pharmaceuticals U.S.A., Inc.$447K
  • Bristol Myers Squibb$393K
  • plus $720K from 12 others
$7,340in research payments, 2019–2025

Across 8 payments — averaging $917.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$7K

What the payments were for

  • Consulting fees$3,50072%
  • Speaking & faculty fees$1,27026%
  • Food & beverage$451%
  • Education$311%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,323,640 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$32,559
Medicare patients
173
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide53$712,603
CalquenceAcalabrutinib Maleate29$433,259
ImbruvicaIbrutinib16$253,700
TasignaNilotinib Hcl12$234,866
Lenalidomide22$197,586
EliquisApixaban53$33,177
XareltoRivaroxaban12$15,203
OxycontinOxycodone Hcl13$13,707
Abiraterone Acetate12$9,512
Anastrozole137$2,793
Tamoxifen Citrate42$1,252
Dexamethasone44$973
Letrozole36$906
Prochlorperazine Maleate31$630
Oxycodone Hcl89$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$63,732$433,25929 claims
NovartisTasigna$2,379,754$234,86612 claims
PfizerEliquis$487,953$33,17753 claims
Lilly USA, LLCOlanzapine$20$6821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.

Other hematology & oncology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →